480998-38-7

Upstream product

• 3934-20-1 2,6-Dichloropyrimidine 
• 105-13-5 4-Methoxybenzyl alcohol 

Downstream Products

• 1268273-93-3 4-(4-methoxybenzyloxy)-2-(4-methylpiperazin-1-yl)pyrimidine 
• 1448788-57-5 C₂₁H₂₂N₂O₅ 
• 1352571-59-5 C₃₀H₄₄N₂O₄Si₂ 
• 1352570-87-6 3-cyclobutoxy-5-(4-(4-methoxybenzyloxy)pyrimidin-2-yl)phenol 
• 1352570-86-5 2-(3-cyclobutoxy-5-(triisopropylsilyloxy)phenyl)-4-(4-methoxybenzyloxy)pyrimidine 
• 1352571-38-0 3-(4-(4-methoxybenzyloxy)pyrimidin-2-yl)-5-((2S,3R)-3-(tert-butyldimethylsilyloxy)butan-2-yloxy)phenol 
• 1352571-00-6 3-(4-(4-methoxybenzyloxy)pyrimidin-2-yl)-5-((S)-1-(tert-butyldimethylsilyloxy)propan-2-yloxy)phenol 
• 1352571-63-1 C₂₈H₃₈N₂O₄Si 
• 1352571-11-9 (S)-3-sec-butoxy-5-(4-(4-methoxybenzyloxy)pyrimidin-2-yl)phenol 
• 1352571-61-9 C₂₇H₃₆N₂O₄Si 
• 1352571-50-6 4-(4-methoxybenzyloxy)-2-(3-((S)-1-methoxypropan-2-yloxy)-5-(4-(methylsulfonyl)phenoxy)phenyl)pyrimidine 
• 1352571-49-3 C₃₆H₄₆N₂O₇SSi 
• 1352571-64-2 C₂₈H₂₉N₅O₅ 

Relevant academic research and scientific papers

TRICYCLIC COMPOUNDS AND THEIR USE

Tricyclic compounds and their use are provided. More specifically, tricyclic compounds, pharmaceutical compositions containing them, methods for preparing them, and their use in therapy are also provided.

Pyrimidone-based series of glucokinase activators with alternative donor-acceptor motif

Glucokinase activators are a class of experimental agents under investigation as a therapy for Type 2 diabetes mellitus. An X-ray crystal structure of a modestly potent agent revealed the potential to substitute the common heterocyclic amide donor-acceptor motif for a pyridone moiety. We have successfully demonstrated that both pyridone and pyrimidone heterocycles can be used as a potent donor-acceptor substituent. Several sub-micromolar analogs that possess the desired partial activator profile were synthesized and characterized. Unfortunately, the most potent activators suffered from sub-optimal pharmacokinetic properties. Nonetheless, these donor-acceptor motifs may find utility in other glucokinase activator series or beyond.

HEAT SHOCK PROTEIN BINDING COMPOUNDS, COMPOSITIONS, AND METHODS FOR MAKING AND USING SAME

The present subject matter relates to a compound represented by the general formula (I) or (I') or a pharmacologically acceptable salt thereof; pharmaceutical compositions containing at least one of these compounds; methods of making at least one of these compounds; methods of using at least one of these compounds for treating and/or preventing various cancers and/or proliferation disorders; methods of using at least one of these compounds for monitoring the effectiveness of an anticancer therapy against various cancers. In one embodiment, the subject matter relates to compounds that bind with a level of specificity to heat shock protein 70 (Hsp70). In another embodiment, the subject matter relates to compounds that bind with a level of specificity to inhibit both heat shock protein 70 (Hsp70) and heat shock cognate protein 70 (Hsc70).

2-(3,5-DISUBSTITUTEDPHENYL)PYRIMIDIN-4(3H)-ONE DERIVATIVES

O N NH R3 R2 O R1 168 ABSTRACT The present invention provides a 2-(3,5-disubstitutedphenyl)pyrimidin- 4(3H)-one compound of Formula (I) 5 (I) or a pharmaceutically acceptable salt thereof wherein R 1, R2 and R3 are as defined herein. The compounds of Formula (I) have been found to act as glucokinase activators. Consequently, the compounds of Formula (I) and 10 the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucokinase.